Equated, a Scottish manufacturer of fatty acid compounds, has developed a method to synthetise the omega-6 fatty acid Dihomma-Gamma-Linolenic Acid (DGLA).

DGLA is well documented for its anti-inflammatory actions but, despite its interest, this substance was not easily accessible from natural source and therefore hardly available. Synthetic DGLA produced by Equated will be marketed under the trade-name EQT-101, and is now avaible for research, pharmaceutical and cosmetic industries from gram to kilogram “For anyone interested in the business of smooth healthy skin,” Equateq CEO, Adam Kelliher, said.